Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NCT05707949 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

650

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Prophylaxis

Interventions

DRUG: Atogepant

Sponsor

AbbVie